Rezolute, Inc. (NASDAQ:RZLT) Receives $14.50 Average PT from Analysts

Rezolute, Inc. (NASDAQ:RZLT) has earned an average recommendation of “Moderate Buy” from the eight analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $14.50.

Several analysts have recently commented on the stock. BTIG Research restated a “buy” rating and set a $17.00 price objective on shares of Rezolute in a research report on Thursday, September 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Rezolute in a research report on Saturday. Maxim Group raised their target price on shares of Rezolute from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, September 18th. Guggenheim reaffirmed a “buy” rating and set a $15.00 target price on shares of Rezolute in a research note on Monday, September 22nd. Finally, Wedbush reissued an “outperform” rating and issued a $12.00 price objective on shares of Rezolute in a research note on Thursday, September 18th.

Hedge Funds Weigh In On Rezolute

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets purchased a new position in shares of Rezolute in the 2nd quarter worth $25,000. Ameritas Investment Partners Inc. purchased a new position in shares of Rezolute in the 2nd quarter worth $30,000. Legal & General Group Plc purchased a new position in shares of Rezolute in the 2nd quarter worth $32,000. Raymond James Financial Inc. purchased a new position in shares of Rezolute in the 2nd quarter worth $46,000. Finally, Jeppson Wealth Management LLC purchased a new position in shares of Rezolute in the 1st quarter worth $35,000. 82.97% of the stock is owned by hedge funds and other institutional investors.

Rezolute Trading Up 1.9%

RZLT opened at $9.19 on Thursday. Rezolute has a 1-year low of $2.21 and a 1-year high of $10.04. The company has a market capitalization of $834.73 million, a PE ratio of -9.47 and a beta of 0.04. The firm’s 50 day simple moving average is $8.14 and its two-hundred day simple moving average is $5.73.

Rezolute (NASDAQ:RZLT) last released its quarterly earnings results on Wednesday, September 17th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.03). Equities analysts forecast that Rezolute will post -0.93 earnings per share for the current fiscal year.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.